JFLLIFE Stock Overview
Engages in the manufacture and sale of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
JFL Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹32.35 |
| 52 Week High | ₹37.15 |
| 52 Week Low | ₹12.02 |
| Beta | -0.53 |
| 1 Month Change | -4.15% |
| 3 Month Change | 47.05% |
| 1 Year Change | 122.85% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 45.94% |
Recent News & Updates
A Piece Of The Puzzle Missing From JFL Life Sciences Limited's (NSE:JFLLIFE) 26% Share Price Climb
Nov 13
Even With A 27% Surge, Cautious Investors Are Not Rewarding JFL Life Sciences Limited's (NSE:JFLLIFE) Performance Completely
Sep 17Recent updates
A Piece Of The Puzzle Missing From JFL Life Sciences Limited's (NSE:JFLLIFE) 26% Share Price Climb
Nov 13Even With A 27% Surge, Cautious Investors Are Not Rewarding JFL Life Sciences Limited's (NSE:JFLLIFE) Performance Completely
Sep 17Further Upside For JFL Life Sciences Limited (NSE:JFLLIFE) Shares Could Introduce Price Risks After 27% Bounce
Jul 05Shareholder Returns
| JFLLIFE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.0% | 0.8% | -4.2% |
| 1Y | 122.8% | 39.7% | 19.1% |
Return vs Industry: JFLLIFE exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: JFLLIFE exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| JFLLIFE volatility | |
|---|---|
| JFLLIFE Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: JFLLIFE's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: JFLLIFE's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Smiral Patel | www.jfllifesciences.com |
JFL Life Sciences Limited engages in the manufacture and sale of pharmaceutical products in India and internationally. It offers B-Lactam dry powder injections, and solid oral dosage form tablets and capsules; general solid oral dosage form tablets and capsules; and oral rehydration solutions. The company was incorporated in 2010 and is headquartered in Ahmedabad, India.
JFL Life Sciences Limited Fundamentals Summary
| JFLLIFE fundamental statistics | |
|---|---|
| Market cap | ₹1.07b |
| Earnings (TTM) | ₹53.63m |
| Revenue (TTM) | ₹749.06m |
19.9x
P/E Ratio1.4x
P/S RatioIs JFLLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JFLLIFE income statement (TTM) | |
|---|---|
| Revenue | ₹749.06m |
| Cost of Revenue | ₹638.33m |
| Gross Profit | ₹110.73m |
| Other Expenses | ₹57.10m |
| Earnings | ₹53.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.63 |
| Gross Margin | 14.78% |
| Net Profit Margin | 7.16% |
| Debt/Equity Ratio | 26.9% |
How did JFLLIFE perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield3%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 06:02 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
JFL Life Sciences Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|